282 related articles for article (PubMed ID: 27854302)
1. Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation.
Su SC; Hung SI; Fan WL; Dao RL; Chung WH
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27854302
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Kaniwa N; Saito Y
J Hum Genet; 2013 Jun; 58(6):317-26. PubMed ID: 23635947
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Borroni RG
G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
[TBL] [Abstract][Full Text] [Related]
4. Genetics and the potential for predictive tests in adverse drug reactions.
Pirmohamed M
Chem Immunol Allergy; 2012; 97():18-31. PubMed ID: 22613851
[TBL] [Abstract][Full Text] [Related]
5. Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.
Gerogianni K; Tsezou A; Dimas K
Mol Diagn Ther; 2018 Jun; 22(3):297-314. PubMed ID: 29564734
[TBL] [Abstract][Full Text] [Related]
6. HLA alleles and drug hypersensitivity reactions.
Profaizer T; Eckels D
Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
[TBL] [Abstract][Full Text] [Related]
8. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI
Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
[TBL] [Abstract][Full Text] [Related]
9. [The associations between idiosyncratic adverse drug reactions and HLA alleles and their underlying mechanism].
Wang Q; Mei H; Zhang YL; Pan XC; Tan W; Chao L
Yao Xue Xue Bao; 2013 Jun; 48(6):799-808. PubMed ID: 23984511
[TBL] [Abstract][Full Text] [Related]
10. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions.
Kano Y; Hirahara K; Asano Y; Shiohara T
Acta Derm Venereol; 2008; 88(6):616-8. PubMed ID: 19002350
[No Abstract] [Full Text] [Related]
11. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.
Fernando SL; Broadfoot AJ
CMAJ; 2010 Mar; 182(5):476-80. PubMed ID: 19933789
[No Abstract] [Full Text] [Related]
12. Human leukocyte antigens and drug hypersensitivity.
Chung WH; Hung SI; Chen YT
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
[TBL] [Abstract][Full Text] [Related]
13. [Exploratory study on biomarkers associated with severe cutaneous adverse reactions].
Kaniwa N
Yakugaku Zasshi; 2011 Feb; 131(2):255-61. PubMed ID: 21297371
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.
Caldarola G; Sollena P; Peris K; De Simone C
J Dermatol; 2015 Jul; 42(7):753-4. PubMed ID: 25899558
[No Abstract] [Full Text] [Related]
15. Genotyping for severe drug hypersensitivity.
Karlin E; Phillips E
Curr Allergy Asthma Rep; 2014 Mar; 14(3):418. PubMed ID: 24429903
[TBL] [Abstract][Full Text] [Related]
16. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
[TBL] [Abstract][Full Text] [Related]
17. A Personalized Medicine Approach to Guide Allopurinol Use and Prevent Serious Adverse Events: Ethnicity Is Not a Proxy for Genetics.
Ikediobi O
Clin Pharmacol Ther; 2021 Oct; 110(4):852-854. PubMed ID: 33330976
[No Abstract] [Full Text] [Related]
18. Allopurinol pharmacogenetics: assessment of potential clinical usefulness.
Zineh I; Mummaneni P; Lyndly J; Amur S; La Grenade LA; Chang SH; Rogers H; Pacanowski MA
Pharmacogenomics; 2011 Dec; 12(12):1741-9. PubMed ID: 22118056
[TBL] [Abstract][Full Text] [Related]
19. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.
Kang HR; Jee YK; Kim YS; Lee CH; Jung JW; Kim SH; Park HW; Chang YS; Jang IJ; Cho SH; Min KU; Kim SH; Lee KW;
Pharmacogenet Genomics; 2011 May; 21(5):303-7. PubMed ID: 21301380
[TBL] [Abstract][Full Text] [Related]
20. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.
Cheng L; Xiong Y; Qin CZ; Zhang W; Chen XP; Li J; Zhou HH
Br J Dermatol; 2015 Aug; 173(2):555-8. PubMed ID: 26104483
[No Abstract] [Full Text] [Related]
[Next] [New Search]
